{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:38:52Z","timestamp":1786117132485,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.alit.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:19:40Z","timestamp":1784067580000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Randomized phase 2a study of TAS5315, a Bruton\u2019s tyrosine kinase inhibitor, for chronic spontaneous urticaria"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1569-6034","authenticated-orcid":false,"given":"Michihiro","family":"Hide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-2493","authenticated-orcid":false,"given":"Koremasa","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1989-9824","authenticated-orcid":false,"given":"Naoko","family":"Inomata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Takahagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokuya","family":"Omi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2026.06.003_bib1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2026.06.003_bib2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/1346-8138.14502","article-title":"Impact of chronic urticaria on quality of life and work in Japan: results of a real-world study","volume":"45","author":"Itakura","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2026.06.003_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.iac.2013.09.011","article-title":"Urticaria: impact on quality of life and economic cost","volume":"34","author":"O\u2019Donnell","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.alit.2026.06.003_bib5","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/all.13209","article-title":"The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU","volume":"72","author":"Maurer","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2026.06.003_bib6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13555-025-01348-8","article-title":"Urticaria voices: real-world experience of patients living with chronic spontaneous urticaria","volume":"15","author":"Weller","year":"2025","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.alit.2026.06.003_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3904\/kjim.2015.195","article-title":"Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria","volume":"33","author":"Choi","year":"2018","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.alit.2026.06.003_bib8","first-page":"1394","article-title":"Japanese Guidelines for Diagnosis and Treatment of Urticaria 2018","volume":"67","author":"Hide","year":"2018","journal-title":"Arerugi"},{"key":"10.1016\/j.alit.2026.06.003_bib9","first-page":"1181","article-title":"Japanese Guidelines for Diagnosis and Treatment of Urticaria 2018","volume":"68","author":"Fukunaga","year":"2019","journal-title":"Arerugi"},{"key":"10.1016\/j.alit.2026.06.003_bib10","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/bcp.70039","article-title":"Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: first-in-human, randomized, ascending-dose studies","volume":"91","author":"Kumagai","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.alit.2026.06.003_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282117","article-title":"Novel Bruton\u2019s tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis","volume":"18","author":"Akasaka","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.alit.2026.06.003_bib12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0952-7915(00)00088-1","article-title":"Tec family kinases in lymphocyte signaling and function","volume":"12","author":"Schaeffer","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000078339","article-title":"The role of Tec family kinases in myeloid cells","volume":"134","author":"Schmidt","year":"2004","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","article-title":"BTK signaling\u2013a crucial link in the pathophysiology of chronic spontaneous urticaria","volume":"153","author":"Bernstein","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib15","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.anai.2024.08.049","article-title":"Bruton\u2019s Tyrosine Kinase inhibitor TAS5315 showed long-lasting hive-free condition in patients with chronic spontaneous urticaria","volume":"133","author":"Hide","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.alit.2026.06.003_bib17","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cell.2007.12.037","article-title":"Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals","volume":"132","author":"Shinohara","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.alit.2026.06.003_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014A simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.alit.2026.06.003_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000507218","article-title":"Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020","volume":"181","author":"Maurer","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40265-025-02170-4","article-title":"Update on the treatment of chronic spontaneous urticaria","volume":"85","author":"Kolkhir","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.alit.2026.06.003_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","article-title":"Rilzabrutinib in antihistamine-refractory chronic spontaneous urticaria: the RILECSU phase 2 randomized clinical trial","volume":"161","author":"Gim\u00e9nez-Arnau","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2026.06.003_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.alit.2018.11.003","article-title":"The Urticaria Control Test and Urticaria Activity Score correlate with quality of life in adult Japanese patients with chronic spontaneous urticaria","volume":"68","author":"Nakatani","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2026.06.003_bib24","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1002\/eji.200838839","article-title":"The protein tyrosine kinase Tec regulates mast cell function","volume":"39","author":"Schmidt","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.920","article-title":"The correlation between Th17\/Treg immune dysregulation and the disease severity in chronic spontaneous urticaria patients","volume":"11","author":"Yang","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.alit.2026.06.003_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18187-z","article-title":"Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria","volume":"7","author":"Lin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.alit.2026.06.003_bib27","article-title":"In silico identification of immune cell-types and pathways involved in chronic spontaneous urticaria","volume":"9","author":"Prosty","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.alit.2026.06.003_bib28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4168\/aair.2025.17.5.531","article-title":"An overview of chronic spontaneous urticaria: diagnosis, management, and treatment","volume":"17","author":"Tbakhi","year":"2025","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.alit.2026.06.003_bib29","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.anai.2024.08.087","article-title":"Bruton\u2019s Tyrosine Kinase inhibitor, TAS5315, as a potential therapeutic agent against chronic spontaneous urticaria","volume":"133","author":"Kajiwara","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BST20190486","article-title":"Tuning T helper cell differentiation by ITK","volume":"48","author":"Elmore","year":"2020","journal-title":"Biochem Soc Transact"},{"key":"10.1016\/j.alit.2026.06.003_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.it.2006.08.006","article-title":"Itk and Th2 responses: action but no reaction","volume":"27","author":"Kosaka","year":"2006","journal-title":"Trends Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib32","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/all.16243","article-title":"Disease modification in chronic spontaneous urticaria","volume":"79","author":"Maurer","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2026.06.003_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40261-024-01389-5","article-title":"The effect of placebo on pruritus in patients with chronic urticaria: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"44","author":"Xue","year":"2024","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.alit.2026.06.003_bib34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4168\/aair.2017.9.6.477","article-title":"Chronic spontaneous urticaria: pathogenesis and treatment considerations","volume":"9","author":"Kaplan","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.alit.2026.06.003_bib35","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.alit.2026.06.003_bib36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jdermsci.2017.03.009","article-title":"Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria","volume":"87","author":"Hide","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.alit.2026.06.003_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.06.003_bib38","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2026.06.003_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.749022","article-title":"Effects of the BTK inhibitors remibrutinib (LOU064) and rilzabrutinib (PRN1008) with varying BTK selectivity over Tec on platelet aggregation and in vitro bleeding time","volume":"8","author":"Duan","year":"2021","journal-title":"Front Cardiovasc Med"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893026000791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893026000791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:23:05Z","timestamp":1786022585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893026000791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S1323893026000791"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2026.06.003","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized phase 2a study of TAS5315, a Bruton\u2019s tyrosine kinase inhibitor, for chronic spontaneous urticaria","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Allergology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}